ETC
Exchange Traded Concepts Portfolio holdings
AUM
$7.83B
1-Year Return
24.45%
This Quarter Return
+7.15%
1 Year Return
+24.45%
3 Year Return
+83.69%
5 Year Return
+131.49%
10 Year Return
–
AUM
$4.06B
AUM Growth
+$411M
(+11%)
Cap. Flow
+$232M
Cap. Flow
% of AUM
5.72%
Top 10 Holdings %
Top 10 Hldgs %
21.64%
Holding
1,420
New
288
Increased
397
Reduced
560
Closed
115
Top Buys
| 1 |
Vanguard Long-Term Bond ETF
BLV
|
+$158M |
| 2 |
iShares Core US REIT ETF
USRT
|
+$141M |
| 3 |
Technology Select Sector SPDR Fund
XLK
|
+$138M |
| 4 |
Vanguard Extended Market ETF
VXF
|
+$101M |
| 5 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$69.2M |
Top Sells
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$731M |
| 2 |
Goldman Sachs Access Treasury 0-1 Year ETF
GBIL
|
+$487M |
| 3 |
NVIDIA
NVDA
|
+$38.6M |
| 4 |
Verizon
VZ
|
+$19.7M |
| 5 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$18.9M |
Sector Composition
| 1 | Technology | 20.92% |
| 2 | Energy | 10.24% |
| 3 | Healthcare | 10.11% |
| 4 | Industrials | 5.82% |
| 5 | Consumer Discretionary | 5.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
851
Nuvation Bio
NUVB
$1.15B
| $144K | ﹤0.01% |
+79,856
| New | +$144K |
|
|
VECT
852
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $144K | ﹤0.01% |
+8,512
| New | +$144K |
|
853
CBIZ
CBZ
$3.01B
| $143K | ﹤0.01% |
+2,693
| New | +$143K |
|
854
Select Water Solutions
WTTR
$930M
| $143K | ﹤0.01% |
+17,653
| New | +$143K |
|
855
Zymeworks
ZYME
$1.15B
| $143K | ﹤0.01% |
+16,528
| New | +$143K |
|
856
Merus
MRUS
$5.28B
| $143K | ﹤0.01% |
+5,419
| New | +$143K |
|
857
Wells Fargo
WFC
$260B
| $142K | ﹤0.01% |
3,330
-450
| -12% | -$19.2K |
|
858
Arcus Biosciences
RCUS
$1.25B
| $142K | ﹤0.01% |
+6,975
| New | +$142K |
|
859
Enliven Therapeutics
ELVN
$1.14B
| $142K | ﹤0.01% |
+6,934
| New | +$142K |
|
860
Deckers Outdoor
DECK
$17.5B
| $141K | ﹤0.01% |
1,608
-696
| -30% | -$61.2K |
|
861
Aura Biosciences
AURA
$400M
| $141K | ﹤0.01% |
+11,426
| New | +$141K |
|
862
Genmab
GMAB
$17.6B
| $140K | ﹤0.01% |
+3,696
| New | +$140K |
|
863
Geron
GERN
$842M
| $140K | ﹤0.01% |
+43,602
| New | +$140K |
|
|
EQRX
864
DELISTED
EQRx, Inc. Common Stock
EQRX
| $139K | ﹤0.01% |
+74,812
| New | +$139K |
|
865
Lyell Immunopharma
LYEL
$251M
| $139K | ﹤0.01% |
+2,187
| New | +$139K |
|
|
DCPH
866
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $138K | ﹤0.01% |
+9,803
| New | +$138K |
|
|
THRX
867
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $138K | ﹤0.01% |
+14,791
| New | +$138K |
|
868
Compass Therapeutics
CMPX
$606M
| $137K | ﹤0.01% |
+43,205
| New | +$137K |
|
869
Nuvalent
NUVL
$5.93B
| $137K | ﹤0.01% |
+3,249
| New | +$137K |
|
870
Replimune Group
REPL
$469M
| $137K | ﹤0.01% |
+5,898
| New | +$137K |
|
871
Immatics
IMTX
$706M
| $136K | ﹤0.01% |
+11,816
| New | +$136K |
|
872
Ginkgo Bioworks
DNA
$618M
| $136K | ﹤0.01% |
+1,832
| New | +$136K |
|
873
Best Buy
BBY
$16.1B
| $136K | ﹤0.01% |
1,658
-32,541
| -95% | -$2.67M |
|
|
RAIN
874
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $135K | ﹤0.01% |
+112,812
| New | +$135K |
|
|
MRTX
875
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $135K | ﹤0.01% |
+3,737
| New | +$135K |
|